Neoadjuvant hormonal therapy prior to radical prostatectomy

F. Civantos, S. Sadek, C. Obek, S. Lai, M. Soloway, S. Howell, M. Gleave, F. Labrie, W. Fair, A. D'Amico, N. Stone, D. Grignon

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The US T(2b) study of 3 months of neoadjuvant hormonal therapy (NHT) showed a reduction in the likelihood of positive margins from 48% (control group) to 18% in the treated patients. Follow-up at 42 months shows that the cumulative relapse rate (prostate specific antigen) for 129 patients having NHT was not statistically different from that of the 126 control patients. Because the T(2b) study has been criticized for lacking central pathology review, we present a review of a series involving only one surgeon (MS) and one pathologist (FC) of NHT plus prostatectomy (109 patients) v prostatectomy alone (145 patients) with 24 months' follow-up. Positive margins were decreased from 38% in the untreated to 28% in the treated group, the only statistically significant difference in the results. Biochemical recurrence (PSA >0.2 ng/mL) was higher in the treated group, reflecting selection of more aggressive tumors for NHT, but the difference was not statistically significantly. The incidence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis was similar in the two groups. The largest nonrandomized experience with NHT shows a decrease in the incidence of positive surgical margins when used in high-risk patients with clinically localized carcinoma of the prostate. However, it does not have an impact on disease-free survival at a mean 24-month follow-up.

Original languageEnglish (US)
Pages (from-to)201-206
Number of pages6
JournalMolecular Urology
Issue number3
StatePublished - 1999
Externally publishedYes

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Neoadjuvant hormonal therapy prior to radical prostatectomy'. Together they form a unique fingerprint.

Cite this